Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259336 | 0.88 | SLC1A2 (0.60) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL25242066 | 0.88 | SLC1A2 (0.60) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL25209028 | 0.88 | SLC1A2 (0.60) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL2910863 | 0.87 | SLC1A2 (0.59) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL25216971 | 0.84 | SLC1A2 (0.56) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL25228874 | 0.84 | SLC1A2 (0.56) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL25207395 | 0.84 | SLC1A2 (0.56) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL1397059 | 0.82 | RIPK1 (0.55) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL27472283 | 0.82 | RIPK1 (0.55) | SLC1A2RIPK1HPGDALDH1A1MAPT | |
| SCHEMBL12757444 | 0.82 | SLC1A2 (0.47) | SLC1A2HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCHERING CORPORATION | 2012-08-30 | — | — | US | disclosed |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCHERING CORPORATION | 2012-08-30 | — | — | US | disclosed |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1586552-B1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL IND CO (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-7326813-B2 | Process for producing benzylamine derivative | IHARA CHEMICAL INDUSTRY (JP) | 2008-02-05 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20060155141-A1 | Process for producing benzylamine derivative | ITO AKINORI | 2006-07-13 | — | — | US | disclosed |
| EP-1586552-A1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | SLC1A2 4105/4885RIPK1 1935/4885HPGD 253/4885 |
| US-20060155141-A1 | Process for producing benzylamine derivative | BRD7, BRD1, BRD2 | SLC1A2 1490/4885RIPK1 4019/4885HPGD 2426/4885 |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCD, SCD5, CPT1A | SLC1A2 3665/4885RIPK1 2209/4885HPGD 470/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | SLC1A2 3680/4885RIPK1 2162/4885HPGD 954/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | SLC1A2 3530/4885RIPK1 2170/4885HPGD 954/4885 |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | SLC1A2 3795/4885RIPK1 2650/4885HPGD 1122/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | SLC1A2 3415/4885RIPK1 682/4885HPGD 1510/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | SLC1A2 3530/4885RIPK1 2170/4885HPGD 954/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | SLC1A2 803/4885RIPK1 3585/4885HPGD 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.